Cargando…
Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
BACKGROUND: The aim of this study was to evaluate the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy following first-line FOLFIRINOX treatment failure in advanced pancreatic cancer. METHODS: This was a multicenter, single-arm, open-label, phase 2 trial done...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591648/ https://www.ncbi.nlm.nih.gov/pubmed/34790261 http://dx.doi.org/10.1177/17588359211056179 |
_version_ | 1784599295980208128 |
---|---|
author | Huh, Gunn Lee, Hee Seung Choi, Jin Ho Lee, Sang Hyub Paik, Woo Hyun Ryu, Ji Kon Kim, Yong-Tae Bang, Seungmin Lee, Eaum Seok |
author_facet | Huh, Gunn Lee, Hee Seung Choi, Jin Ho Lee, Sang Hyub Paik, Woo Hyun Ryu, Ji Kon Kim, Yong-Tae Bang, Seungmin Lee, Eaum Seok |
author_sort | Huh, Gunn |
collection | PubMed |
description | BACKGROUND: The aim of this study was to evaluate the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy following first-line FOLFIRINOX treatment failure in advanced pancreatic cancer. METHODS: This was a multicenter, single-arm, open-label, phase 2 trial done at three tertiary centers in South Korea from May 2018 to December 2019. Eligible patients were aged 20 years or older, had histologically confirmed advanced pancreatic ductal adenocarcinoma, and disease progression after receiving first-line FOLFIRINOX. Patients received a second-line GnP regimen as intravenous nab-paclitaxel at a dose of 125 mg/m(2) and gemcitabine at a dose of 1000 mg/m(2), on days 1, 8, and 15 every 4 weeks until disease progression or unacceptable toxicity. The primary outcome was survival rate at 6 months and the secondary outcomes were median progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and adverse events. This study is registered with Clinicaltrials.gov. (NCT03401827) RESULTS: Forty patients were enrolled in the study. The survival rate at 6 months was 72.5% [95% confidence interval (CI), 59.9–87.7], achieving superiority over prespecified assumed 6-month OS rate of 20% for best supportive care only (p < 0.001). The median PFS and OS were 5.8 months (95% CI, 4.3–8.7) and 9.9 months (95% CI, 7.5–12.4), respectively. DCR was 87.5% with six partial responses and 29 stable diseases. Grade 3 or higher treatment-related adverse events occurred in 25 (62.5%) patients with the most common being thrombocytopenia, anemia, neutropenia, peripheral neuropathy, and peripheral edema. CONCLUSION: GnP demonstrated favorable efficacy with acceptable toxicity in patients with advanced pancreatic ductal adenocarcinoma after FOLFIRINOX failure. |
format | Online Article Text |
id | pubmed-8591648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-85916482021-11-16 Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial Huh, Gunn Lee, Hee Seung Choi, Jin Ho Lee, Sang Hyub Paik, Woo Hyun Ryu, Ji Kon Kim, Yong-Tae Bang, Seungmin Lee, Eaum Seok Ther Adv Med Oncol Original Research BACKGROUND: The aim of this study was to evaluate the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy following first-line FOLFIRINOX treatment failure in advanced pancreatic cancer. METHODS: This was a multicenter, single-arm, open-label, phase 2 trial done at three tertiary centers in South Korea from May 2018 to December 2019. Eligible patients were aged 20 years or older, had histologically confirmed advanced pancreatic ductal adenocarcinoma, and disease progression after receiving first-line FOLFIRINOX. Patients received a second-line GnP regimen as intravenous nab-paclitaxel at a dose of 125 mg/m(2) and gemcitabine at a dose of 1000 mg/m(2), on days 1, 8, and 15 every 4 weeks until disease progression or unacceptable toxicity. The primary outcome was survival rate at 6 months and the secondary outcomes were median progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and adverse events. This study is registered with Clinicaltrials.gov. (NCT03401827) RESULTS: Forty patients were enrolled in the study. The survival rate at 6 months was 72.5% [95% confidence interval (CI), 59.9–87.7], achieving superiority over prespecified assumed 6-month OS rate of 20% for best supportive care only (p < 0.001). The median PFS and OS were 5.8 months (95% CI, 4.3–8.7) and 9.9 months (95% CI, 7.5–12.4), respectively. DCR was 87.5% with six partial responses and 29 stable diseases. Grade 3 or higher treatment-related adverse events occurred in 25 (62.5%) patients with the most common being thrombocytopenia, anemia, neutropenia, peripheral neuropathy, and peripheral edema. CONCLUSION: GnP demonstrated favorable efficacy with acceptable toxicity in patients with advanced pancreatic ductal adenocarcinoma after FOLFIRINOX failure. SAGE Publications 2021-11-10 /pmc/articles/PMC8591648/ /pubmed/34790261 http://dx.doi.org/10.1177/17588359211056179 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Huh, Gunn Lee, Hee Seung Choi, Jin Ho Lee, Sang Hyub Paik, Woo Hyun Ryu, Ji Kon Kim, Yong-Tae Bang, Seungmin Lee, Eaum Seok Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial |
title | Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial |
title_full | Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial |
title_fullStr | Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial |
title_full_unstemmed | Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial |
title_short | Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial |
title_sort | gemcitabine plus nab-paclitaxel as a second-line treatment following folfirinox failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591648/ https://www.ncbi.nlm.nih.gov/pubmed/34790261 http://dx.doi.org/10.1177/17588359211056179 |
work_keys_str_mv | AT huhgunn gemcitabineplusnabpaclitaxelasasecondlinetreatmentfollowingfolfirinoxfailureinadvancedpancreaticcanceramulticentersinglearmopenlabelphase2trial AT leeheeseung gemcitabineplusnabpaclitaxelasasecondlinetreatmentfollowingfolfirinoxfailureinadvancedpancreaticcanceramulticentersinglearmopenlabelphase2trial AT choijinho gemcitabineplusnabpaclitaxelasasecondlinetreatmentfollowingfolfirinoxfailureinadvancedpancreaticcanceramulticentersinglearmopenlabelphase2trial AT leesanghyub gemcitabineplusnabpaclitaxelasasecondlinetreatmentfollowingfolfirinoxfailureinadvancedpancreaticcanceramulticentersinglearmopenlabelphase2trial AT paikwoohyun gemcitabineplusnabpaclitaxelasasecondlinetreatmentfollowingfolfirinoxfailureinadvancedpancreaticcanceramulticentersinglearmopenlabelphase2trial AT ryujikon gemcitabineplusnabpaclitaxelasasecondlinetreatmentfollowingfolfirinoxfailureinadvancedpancreaticcanceramulticentersinglearmopenlabelphase2trial AT kimyongtae gemcitabineplusnabpaclitaxelasasecondlinetreatmentfollowingfolfirinoxfailureinadvancedpancreaticcanceramulticentersinglearmopenlabelphase2trial AT bangseungmin gemcitabineplusnabpaclitaxelasasecondlinetreatmentfollowingfolfirinoxfailureinadvancedpancreaticcanceramulticentersinglearmopenlabelphase2trial AT leeeaumseok gemcitabineplusnabpaclitaxelasasecondlinetreatmentfollowingfolfirinoxfailureinadvancedpancreaticcanceramulticentersinglearmopenlabelphase2trial |